Venetoclax Schedules, Pharmacokinetic Response, and Activity Against Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). (A) Administration schedule for the 53 patients in the dose escalation cohort. (B) Administration schedule for the 60 patients in the expansion cohort. (C) Plasma levels of venetoclax at steady state, grouped according to the dose at the time of collection. (D-F) Activity of venetoclax against CLL or SLL in blood (D), lymph nodes (E), and bone marrow (F), which are shown as normalized changes from baseline. From New England Journal of Medicine, Roberts AW et al, “Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia,” Volume 374, Page 314. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.